Briumvi’s Phase 3 trial of an at-home injection has completed enrollment, testing an under-the-skin version against IV ...

A woman in her 50s with genetically confirmed Huntington’s disease presented with right-sided arm sensory symptoms that evolved over days and persisted for at least 1 month. Neurological examination ...

Please provide your email address to receive an email when new articles are posted on . Adults either continued to receive ublituximab or switched from teriflunomide to ublituximab in this 3-year open ...

In the above studies in PPMS and RMS, GA Depot showed EDSS stabilization, irrespective of baseline EDSS scores. These EDSS findings suggest GA Depot's potential in slowing disability progression, ...

Please provide your email address to receive an email when new articles are posted on . The most common comorbidity for both subsets of the study population was obesity. Risk for infection-related ...

Phase 3 trial evaluated two subcutaneous BRIUMVI dosing regimens; administration every 2 months or every 3 monthsTop-line data expected year-end ...

Insights from AAN 2026, including anticipated presentations, key takeaways, and how emerging research in RRMS may affect ...

FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), consistent with ...

- FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), consistent with ...

Dr Chu-Yueh Guo prepares to discover how the latest diagnostic criteria and breakthrough treatments are reshaping the ...

Osaka, Japan – One monoclonal antibody, rituximab, can work wonders for the treatment of children with frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome. However, what ...